Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result

Background: The HBeAg-positive chronic hepatitis B is the type of chronic hepatitis with active virus replication, has high viral load and difficult to treat. We evaluate the effects of treatment with tenofovir in HBeAg-positive chronic hepatitis B patients. Aims: Evaluate the treatment results in patients with HBeAg-positive chronic hepatitis B. Patients and methodes: HBeAg-positive chronic hepatitis B patients over 15 yrs treated at Hue University Hospital from Jan. 2012 to Dec. 2013. Results: Most of symptoms disappeared after 12 months. More than 85% patients have biochemical response. 81.8% patients have undetectable HBV DNA. Rate of HBV DNA decrease according to the baseline viral load. After 12 months 27.3% patients loss HBeAg and 20.5% have anti-HBe. Conclusions: Clinical and biochemical response were relatively high. 81.8% patients have undetectable HBV DNA. After 12 months 27.3% patients loss HBeAg and 20.5% have anti-HBe. Key words: HBeAg-positive chronic hepatitis B, HBV DNA

Download Full-text

Efficacy of entecavir treatment for up to 96 weeks in nucleoside-naive HBeAg-positive chronic hepatitis B patients with high viral load

Clinics and Research in Hepatology and Gastroenterology ◽

10.1016/j.clinre.2014.09.009 ◽

2015 ◽

Vol 39 (3) ◽

pp. 366-372 ◽

Cited By ~ 6

Author(s):

Li-Bo Yan ◽

En-Qiang Chen ◽

Lang Bai ◽

Ling-Yao Du ◽

Lan-Lan Chen ◽

...

Keyword(s):

Chronic Hepatitis ◽

Viral Load ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

High Viral Load ◽

Positive Chronic Hepatitis

Download Full-text

Update in management of hepatitis B in pregnancy and prevention of mother to child hepatitis B transmission

Thai Journal of Hepatology ◽

10.30856/th.jhep2018vol1iss3_01 ◽

2018 ◽

Vol 1 (3) ◽

pp. 1-8

Author(s):

Naichaya Chamroonkul

Keyword(s):

Chronic Hepatitis ◽

Viral Load ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

High Viral Load ◽

World Population ◽

Hepatitis B Infection ◽

Mother To Child Transmission ◽

Child Transmission ◽

Mother To Child

Even with two decades of widespread using hepatitis B vaccination, chronic hepatitis B remains a major global health problem. In Thailand, the prevalence of chronic hepatitis B infection was down from 8 - 10% in last decade to 5% recently. Failure to control mother to child transmission is one of the important barriers to the total elimination of hepatitis B infection from world population. In the majority, vertical transmission can be prevented with a universal screening program, immunoprophylaxis by administration of hepatitis B vaccine and hepatitis B immunoglobulin (HBIg) for babies born to mothers with HBV. However, in mothers with a high viral load, the chance of immunoprophylaxis failure remains high. To date, there are standard recommendations by all international liver societies including AASLD, EASL and APASL suggest introducing an antiviral agent during the third trimester to CHB pregnant women with a high viral load. Previous US FDA pregnancy category B agents such as Tenofovir and Telbivudine are allowed through all trimesters of pregnancy and are effective for prevention of mother to child transmission. Breastfeeding for patients who receive antiviral agents can be allowed after a risk-benefit discussion with the patient and family.

Download Full-text